Skip to main content
Clinical Trials/NCT02445430
NCT02445430UnknownNot Applicable

Genetics of Arteriovenous Malformations

St. Joseph's Hospital and Medical Center, Phoenix1 site in 1 country59 target enrollmentStarted: May 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
59
Locations
1
Primary Endpoint
Identification of genetic alterations common to patients with AVM

Study Overview

Brief Summary

The goal of this study is to identify genetic alterations resulting in the development of arteriovenous malformation (AVM) in the central nervous system.

Detailed Description

The study will include AVM patients and members of their nuclear family. All patients will donate a sample of saliva (5 mL) or blood (10 mL). Basic demographic and clinical parameters will be collected, including ethnicity, age at first presentation, symptoms at presentation, history of subsequent symptoms, treatment history, Spetzler-Martin AVM grade, medication history, and other pertinent medical information. In patients undergoing AVM resection, a small sample of the AVM will be collected for concurrent genomic analysis. Family members will donate saliva (5mL) and document their relationship to the patient (i.e., parent, sibling, child, etcl). Nucleic acids will be isolated from the saliva/blood samples, and genetic sequencing will be carried out. When a surgical sample of the AVM is available, nucleic acids will be obtained and transcriptome profiling will be performed. Identification of genetic alterations common to patients with AVM and not present in samples from parents and siblings will greatly aid in identification of pathways associated with AVM formation. Candidate sequences will be chosen by differential expression (p<0.05) and fold-changes. Once identified, mechanisms for the rapid detection of marker sequences will be developed and their predictive value tested in future collections.

Study Design

Study Type
Observational
Observational Model
Family Based
Time Perspective
Prospective

Eligibility Criteria

Ages
6 Years to 60 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age between 6 and 60 years inclusive
  • Diagnosis of AVM or nuclear family member of a patient with AVM
  • Grants access to saliva, blood, and/or tissue

Exclusion Criteria

  • Age less than 6 years or greater than 61 years
  • Nuclear family members who do not share the same parents as the AVM patient

Outcomes

Primary Outcomes

Identification of genetic alterations common to patients with AVM

Time Frame: sample analysis will take an expected average of six weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lisa Arnold

Research Manager

St. Joseph's Hospital and Medical Center, Phoenix

Study Sites (1)

Loading locations...

Similar Trials

Genetics of Arteriovenous Malformations | Clinical Trial